Owen Roberts from M4K Pharma (Medicines for Kids) joins us to discuss how open source approaches can transform drug discovery, particularly for rare and neglected diseases where traditional pharmaceutical business models fall short.
What is M4K Pharma?
M4K Pharma—Medicines for Kids—is an initiative focused on developing treatments for DIPG (Diffuse Intrinsic Pontine Glioma), a rare and almost universally fatal children's brain cancer. What makes M4K unique is its radical commitment to open science: all research data and findings are shared publicly, with no patents filed on discoveries.
DIPG is one of the most devastating childhood cancers. There has been almost no progress in treatment for decades. M4K believes that open science can change this.
The Open Science Model
The traditional pharmaceutical model relies heavily on patents and trade secrets to protect intellectual property and generate return on investment. M4K takes the opposite approach:
- All research data is shared publicly as soon as it is generated
- No patents are filed on any discoveries
- Anyone can build on the research without restrictions
- Collaboration is open to researchers, institutions, and organizations worldwide
Why Open Source Works for Rare Disease Drug Development
For rare diseases like DIPG, the traditional pharma model often fails. The patient population is too small to generate the kind of revenue that justifies the enormous investment required for drug development. This creates a tragic situation where children die from a disease that receives little commercial attention.
Open source drug discovery addresses this by:
- Reducing duplication: When research is shared openly, multiple labs don't waste resources repeating the same experiments
- Accelerating research: Open access to data and findings allows the global scientific community to contribute and build on each other's work
- Lowering costs: Without the need to recoup patent-related expenses, the overall cost of drug development can be reduced
- Attracting diverse expertise: Open projects draw in contributors with varied skills and perspectives
Collaboration with the Structural Genomics Consortium
M4K Pharma works closely with the Structural Genomics Consortium (SGC) at the University of Toronto. The SGC is a public-private partnership that practices open science in its research on protein structures and chemical probes. This collaboration provides M4K with access to world-class structural biology expertise and chemical libraries.
The Economics of Rare Disease Drug Development
One of the central challenges in rare disease drug development is economics. With small patient populations, the potential revenue from a drug is limited. This means:
- Large pharmaceutical companies have little financial incentive to invest in rare disease R&D
- Venture capital and investment funds seek high returns that rare disease drugs may not provide
- The gap between unmet medical need and commercial viability creates a "valley of death" for rare disease therapies
M4K's open science model offers a way to bridge this gap by dramatically reducing the cost of research and enabling a broader base of funding sources, including philanthropy and government grants.
Community Engagement and Patient Advocacy
A critical aspect of M4K's approach is the role of patient advocacy and community engagement. Families affected by DIPG are active participants in driving research forward. Their passion and urgency provide both motivation and practical support for the open science effort.
Replicating the M4K Model
Perhaps the most exciting aspect of M4K's work is the potential to replicate their model for other rare diseases. If open source drug discovery can work for DIPG, it could work for hundreds of other rare conditions that are currently neglected by the traditional pharmaceutical industry.
The key ingredients for replication include:
- A committed community of researchers and patient advocates
- Institutional support from universities and research organizations
- Funding from non-commercial sources
- A culture of openness and collaboration
Learn More
Visit M4K Pharma to learn more about their work and how you can get involved.
About Bio2040
There are so many challenges in drug discovery. We are a group of entrepreneurs and scientists who want to improve things.
Subscribe to the Podcast on iTunes
Be in the know and sign up for the newsletter.
Follow Flavio on Twitter here.